CardioDynamics International Announces Sale to NASA for Space Research Program.

Business Editors/Health and Medical Writers

SAN DIEGO--(BW HealthWire)--Dec. 29, 1999

Studys Implications May Extend To Home Healthcare

CardioDynamics International Corporation (Nasdaq: CDIC), manufacturer of BioZ(R) noninvasive digital cardiac output monitoring systems, today announced that National Aeronautics and Space Administration (NASA) has placed an additional order for space research. NASAs research study is being conducted in conjunction with the University of San Diego and the University of Pittsburgh.

The study is investigating the long-term adaptation of the cardiovascular system to hypergravity. The investigators theorize that the studys implications will extend beyond the space program and may have applications for the aging and home healthcare. The research may lead to means of stimulating the cardiovascular system, which could have profound effects for numerous patients, including the elderly, congestive heart failure, and home healthcare.

Michael K. Perry, CardioDynamics Chief Executive Officer, stated, "We are very pleased with this recent sale to NASA. This order, together with our recent multi-unit BioZ sales to Brooke Army Medical Center and Veterans Administration hospitals, reinforces the adoption and acceptance of our proprietary technology by government agencies. We are excited about the studys potential applications for the aging and home healthcare as this integrally fits into our Internet medical product development strategy."

Home healthcare visits have grown to 136 million annually, and are estimated to double within the next five years. It is projected that the estimated $400 billion U.S. annual hospitalization costs could be reduced by $50 billion by expanding home healthcare.

Perry added, "With managed care and cost containment pressures driving the expansion of home healthcare, our noninvasive, safe and cost-efficient BioZ systems are a logical choice for expansion of home healthcare services. Our Company has designed products specifically to meet the needs of home healthcare and will continue to tailor our offerings to this explosive market."

The Companys proprietary Impedance Cardiography (ICG) initially was utilized by NASA to monitor the cardiac output of the astronauts in space flight and continues to be chosen by NASA for space research programs because of its ability to accurately and noninvasively produce hemodynamic measurements. The BioZ systems were used also for telemedicine research in the 1998 and 1999 Mount Everest Extreme Expeditions, joint projects of NASA and Yale University.

CardioDynamics, with headquarters in San Diego, is committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The company's primary products, the BioZ(R) System, BioZ(R) Portable, and BioZ.com(TM), utilize Impedance Cardiography (ICG) to noninvasively obtain data on a wide range of hemodynamic parameters. Whereas Electrocardiography (ECG) measures the heart's electrical characteristics, ICG measures the heart's mechanical (blood flow) characteristics. Physicians around the world are currently using the BioZ products, including major medical centers such as the Mayo Clinic (Rochester), UCSF Stanford Health Care (Palo Alto), Yale New Haven Hospital (New Haven), and Baylor College of Medicine (Houston). The worldwide market potential for BioZ products is estimated to be $5 billion, together with an additional $800 million in recurring annual revenue for disposables. For additional information, please refer to the company's Web site at www.cardiodynamics.com.

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, competition from Baxter Healthcare Corp. (manufacturer of the Swan-Ganz(TM) device), further capital requirements, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 1998 Form 10-KSB. The company does not undertake to update the disclosures contained in this press release.